FOIA Request Shows GSK Touted Off-Label Avodart Use

Law360, New York (July 26, 2010, 11:46 AM EDT) -- GlaxoSmithKline PLC reportedly admitted in 2009 that it had not disclosed its role in funding a medical journal supplement that suggested off-label uses for its prostate reduction pill Avodart.

The British company's supplement to the May 2009 edition of Urology contained articles trumpeting Avodart's purported ability to reduce the risk of developing prostate cancer — a use for which the drug has not been approved by the U.S. Food and Drug Administration — and, shortly after publication, GSK sent an apology letter to Urology subscribers describing...
To view the full article, register now.